The ongoing Intergroup LEAP (Less Intense AML Therapy Platform) trial for leukemia is testing a rolling arm “cassette” design where patients are stratified by FLT3 mutation status, in addition to age and performance status, and randomized into treatment arms [15,16]. This evidence concerns the gene FLT3 and acute myeloid leukemia.